Cipla выиграла тендер Глобального фонда на поставку АРВ-препаратов до 2018 года

Cipla, a global pharmaceutical company which uses technology and innovation to meet the everyday needs of all patients - today announced that it has been awarded USD 188.95 million of Global Fund ARV Tender. Cipla has been selected as a ‘Panel Supplier’ for a Supplier Partnership Agreement. The contract is effective from the 1st of January 2015 and will run for a period of three years. The supplies will begin from Q4 FY 2015.

Mr. Subhanu Saxena, MD & Global CEO, Cipla Limited said: “We are extremely proud to have won this tender from Global Fund. Cipla has been committed to the cause of HIV/AIDS for over two decades and this tender offers us a great opportunity to make HIV/AIDS treatment accessible to more than 140 countries through Global Fund.

Cipla has a long-term association with Global Fund since 2002. Last year, Cipla has been one of the suppliers who has been awarded with a long-term contract for supplying anti-malarial drugs.

The anti-retrovirals drugs will be manufactured in Cipla’s state-of-the-art manufacturing facilities in India, which has been approved by various international regulatory agencies.